Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC) Meeting Abstract
| Authors: | Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; Socolow, F.; Chou, J. F.; Capanu, M.; Gerdes, H.; Simmons, M.; Paroder, V.; Tang, L.; Shia, J.; Ilson, D. H.; Janjigian, Y. Y. |
| Abstract Title: | Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1110 |
| Language: | English |
| ACCESSION: | WOS:000866211601488 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2022.07.1345 |
| Notes: | Meeting Abstract: 1227P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
